SAN DIEGO, Sept. 23, 2026 /PRNewswire/ — Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its intention to offer, subject to market and other…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
